The Genomadix Cube
Meet The
Genomadix Cube™
The Genomadix Cube is a fast, accurate, and portable DNA analyzer that gets you quality results outside of a lab.
Rapid Results
Traditional lab-based tests can take days to weeks for results. In contrast, the Genomadix Cube goes from sample to result in approximately an hour, delivering you results faster and making testing more accessible.
Portable
The Genomadix Cube was designed to be used as a decentralized testing option. This is especially helpful for remote communities and remote industries where access to a full lab may be difficult.
Accurate
The Genomadix Cube uses the gold standard of Polymerase Chain Reaction (PCR) to get accurate results, the first time. The Genomadix Cube provides high quality results outside of a lab.
The Genomadix Cube is For:
Health Care Professional
Remote Communities
Medical Distributors
Government Bodies
Commercial Industries
How it works
- Samples are collected and inserted into a single-use DNA test cartridge.
- Inside the analyzer, the cartridge extracts the DNA/RNA and makes millions of copies based on chemistry called Polymerase Chain Reaction (PCR).
- An optical system detects the increased fluorescence and algorithms automatically generate a test result.
High Quality Results
Outside The Lab
While more are in development, our current products include tests for COVID-19, Legionella bacteria, and CYP2C19 genotyping. These tests are run using their own unique software on the Genomadix Cube.
Clinical Studies Leveraging the
Genomadix Cube
New England Journal of Medicine:
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
- This randomized, prospective trial of 2,488 patients undergoing primary PCI with stent implantation assessed the use of a genotype-guided approach to oral P2Y12 inhibitor selection
- This study showed that a genotype-guided approach to therapy was noninferior to standard treatment with ticagrelor or prasugrel with respect to thrombotic events, and resulted in a lower incidence of bleeding
- Considering that ticagrelor/prasugrel cost 10-20X more than generic clopidogrel, CYP2C19 genotyping can significantly lower healthcare costs
The Lancet:
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
- Rapid genetic testing after PCI can be effectively done at the bedside to identify CYP2C19*2 LOF allele carriers
- This prospective, randomized 200-patient study reported that tailored, genotype-guided treatment of CYP2C19*2 carriers can reduce high on-treatment platelet reactivity, which is commonly associated with increased risk for major adverse cardiovascular events
- This study is the first reported use of an FDA-cleared, rapid CYP2C19 genetic test, and offers a novel solution to overcome limitations in pharmacogenomics
Journal of the American Medical Association:
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention
- Genotype-guided therapy resulted in 34% fewer adverse events after 12 months such as death, stroke, second heart attack, and stent thrombosis.
- Genotype-guided therapy resulted in 79% fewer adverse events in the first 3 months. According to principal investigator Dr. Naveen Pereira: “This finding suggests that the lion’s share of the benefit of genetically guided therapy may occur during this high-risk period.”
